Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $220.00 → $255.00 | Neutral → Buy | BofA Securities |
| 5/8/2024 | $265.00 → $225.00 | Buy → Neutral | BofA Securities |
| 4/19/2024 | $285.00 | Outperform | RBC Capital Mkts |
| 3/19/2024 | $250.00 | Overweight | Morgan Stanley |
| 2/6/2024 | $278.00 | Overweight | KeyBanc Capital Markets |
| 1/19/2024 | $245.00 | Buy | Jefferies |
| 1/2/2024 | $210.00 | Buy → Hold | Stifel |
| 12/13/2023 | $245.00 → $187.00 | Overweight → Equal Weight | Wells Fargo |
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously
BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously
RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00
MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspiresl
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in
For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
SD - Inspire Medical Systems, Inc. (0001609550) (Filer)
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)